Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases

Reuters11-07

<a href="https://laohu8.com/S/KPRX">Kiora Pharmaceuticals</a> posts third quarter results and reports ongoing Phase 2 trials for retinal diseases

Kiora Pharmaceuticals Inc. reported third quarter 2025 results, ending the period with $19.4 million in cash, cash equivalents, and short-term investments. The company recorded $1.2 million in collaboration receivables from Théa for reimbursable R&D expenses and $1.5 million in tax and research credit receivables, including $1.0 million from income tax receivables. R&D expenses were $2.7 million for the quarter, before $1.7 million in reimbursable expenses from Théa. This represents an increase from $2.1 million in R&D expenses in the third quarter of 2024, which had $0.9 million in offsetting reimbursable expenses. G&A expenses remained stable at $1.4 million, unchanged from the same period last year. Kiora continues recruitment and patient dosing in its KLARITY Phase 2 trial for KIO-104 and ABACUS-2 Phase 2 trial for KIO-301. The company anticipates a cash runway into late 2027, beyond expected readouts for both clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 273499) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581126009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581126009","market":"fut","top_or_hot":-1,"title":"Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KPRX\">Kiora Pharmaceuticals</a> posts third quarter results and reports ongoing Phase 2 trials for retinal diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiora Pharmaceuticals Inc. reported third quarter 2025 results, ending the period with $19.4 million in cash, cash equivalents, and short-term investments. The company recorded $1.2 million in collaboration receivables from Théa for reimbursable R&amp;D expenses and $1.5 million in tax and research credit receivables, including $1.0 million from income tax receivables. R&amp;D expenses were $2.7 million for the quarter, before $1.7 million in reimbursable expenses from Théa. This represents an increase from $2.1 million in R&amp;D expenses in the third quarter of 2024, which had $0.9 million in offsetting reimbursable expenses. G&amp;A expenses remained stable at $1.4 million, unchanged from the same period last year. Kiora continues recruitment and patient dosing in its KLARITY Phase 2 trial for KIO-104 and ABACUS-2 Phase 2 trial for KIO-301. The company anticipates a cash runway into late 2027, beyond expected readouts for both clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 273499) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KPRX\">Kiora Pharmaceuticals</a> posts third quarter results and reports ongoing Phase 2 trials for retinal diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiora Pharmaceuticals Inc. reported third quarter 2025 results, ending the period with $19.4 million in cash, cash equivalents, and short-term investments. The company recorded $1.2 million in collaboration receivables from Théa for reimbursable R&amp;D expenses and $1.5 million in tax and research credit receivables, including $1.0 million from income tax receivables. R&amp;D expenses were $2.7 million for the quarter, before $1.7 million in reimbursable expenses from Théa. This represents an increase from $2.1 million in R&amp;D expenses in the third quarter of 2024, which had $0.9 million in offsetting reimbursable expenses. G&amp;A expenses remained stable at $1.4 million, unchanged from the same period last year. Kiora continues recruitment and patient dosing in its KLARITY Phase 2 trial for KIO-104 and ABACUS-2 Phase 2 trial for KIO-301. The company anticipates a cash runway into late 2027, beyond expected readouts for both clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 273499) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KPRX","symbol_name":"Kiora Pharmaceuticals","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5kHt78:1","article_id":"2581126009","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581126009","pubTimestamp":1762513294,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kiora Pharmaceuticals Inc. reported third quarter 2025 results, ending the period with $19.4 million in cash, cash equivalents, and short-term investments. The company recorded $1.2 million in collaboration receivables from Théa for reimbursable R&D expenses and $1.5 million in tax and research credit receivables, including $1.0 million from income tax receivables. R&D expenses were $2.7 million for the quarter, before $1.7 million in reimbursable expenses from Théa. This represents an increase from $2.1 million in R&D expenses in the third quarter of 2024, which had $0.9 million in offsetting reimbursable expenses. G&A expenses remained stable at $1.4 million, unchanged from the same period last year. Kiora continues recruitment and patient dosing in its KLARITY Phase 2 trial for KIO-104 and ABACUS-2 Phase 2 trial for KIO-301. The company anticipates a cash runway into late 2027, beyond expected readouts for both clinical trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KPRX":"Kiora Pharmaceuticals","BK4007":"制药"},"translate_title":"Kiora Pharmaceuticals公布第三季度业绩并报告正在进行的视网膜疾病2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPRX":0.9},"content_text":"Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases\n    \n\n        Kiora Pharmaceuticals Inc. reported third quarter 2025 results, ending the period with $19.4 million in cash, cash equivalents, and short-term investments. The company recorded $1.2 million in collaboration receivables from Théa for reimbursable R&D expenses and $1.5 million in tax and research credit receivables, including $1.0 million from income tax receivables. R&D expenses were $2.7 million for the quarter, before $1.7 million in reimbursable expenses from Théa. This represents an increase from $2.1 million in R&D expenses in the third quarter of 2024, which had $0.9 million in offsetting reimbursable expenses. G&A expenses remained stable at $1.4 million, unchanged from the same period last year. Kiora continues recruitment and patient dosing in its KLARITY Phase 2 trial for KIO-104 and ABACUS-2 Phase 2 trial for KIO-301. The company anticipates a cash runway into late 2027, beyond expected readouts for both clinical trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 273499) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581126009","isCrawlerRequest":true}